Welcome to The Catalyst
Change isn't quick. Unless it's when you experience Intravascular Lithotripsy (IVL) for the first time. Stay apprised of our latest news and insights while discovering how a simple and intuitive tool can be The Catalyst to change the way you think about calcium modification.
Topics: Coronary IVL, IVL Technology, SWAV News, Shockwave C2
Topics: Coronary IVL, IVL Technology, SWAV News, Shockwave C2
Q2 is in the books and it was full of electrifying news, big accomplishments and new beginnings. Of course, a major milestone was the acquisition of Shockwave Medical by Johnson & Johnson MedTech. This new journey is off to a great start and we’re excited about how this partnership will help us expand access to our life-changing technologies across the globe.
Updates from the Reducer team for our international physician partners include publishing new data that show positive news for patients suffering from Refractory Angina.* Additionally, our Size for Success training about sizing up for the best Peripheral IVL results is also gaining traction and was featured in several publications. Read the latest PulsePoint Newsletter to learn more about important milestones from Q2!
Topics: Coronary IVL, Peripheral IVL, IVL Technology, Coronary Clinical Data, Peripheral Conferences, Peripheral Clinical Data, SWAV News, Shockwave C2, Coronary Conferences, Shockwave S4, PulsePoint Newsletter, Calcium Corner, Shockwave M5 & Shockwave M5+, Reimbursement, Treating Different Ca++ Morphologies, Female vs. Male Outcomes, Empower CAD, Reducer
Topics: Coronary IVL, IVL Technology, SWAV News, Shockwave C2
Topics: Coronary IVL, IVL Technology, SWAV News, Shockwave C2
There’s no better way to start a new year than building positive momentum. Between great developments on coronary reimbursement to positive real-world data for Reducer, 2024 is off to a shock-worthy start.
Another highlight was the continuous enrollment of patients in our EMPOWER CAD Study — the first prospective clinical study in the interventional space completely dedicated to female patients. Our team also created new resources about optimal sizing for Peripheral IVL, as well as put the final touches on our new manufacturing facility in Costa Rica. Read more about our strong start and get excited about what’s to come in the latest edition of the PulsePoint Newsletter.
Topics: Coronary IVL, Peripheral IVL, IVL Technology, Coronary Clinical Data, Peripheral Conferences, Peripheral Clinical Data, SWAV News, Shockwave C2, Coronary Conferences, Shockwave S4, PulsePoint Newsletter, Calcium Corner, Shockwave M5 & Shockwave M5+, Reimbursement, Treating Different Ca++ Morphologies, Female vs. Male Outcomes, Empower CAD, Reducer
Topics: Coronary IVL, IVL Technology, SWAV News, Shockwave C2
Enrollments in the EMPOWER CAD study are picking up pace! Dr Nieves Gonzalo (Hospital Clìnico San Carlos, Madrid), the study’s European lead, recently shared with the medical community the journey of her first patient included in the study.
Topics: Coronary IVL, IVL Technology, SWAV News, Shockwave C2
Topics: Coronary IVL, IVL Technology, SWAV News, Shockwave C2
What a fantastic finish! From launching the new 120-pulse Shockwave C2+ catheter in the U.S. to establishing a new Category I CPT® Add-on Code for coronary IVL, Q4 was filled with wave-making moments and positive momentum.
One highlight was the release of sex-specific outcomes data for both coronary and peripheral IVL from the DISRUPT PAD III, DISRUPT CAD III and CAD IV studies. Additionally, the DISRUPT PAD III study provided important data supporting the practice of sizing up by 10% for peripheral IVL. Look back at a few of our most noteworthy Q4 accomplishments and get excited about what’s coming in 2024 in the latest issue of the PulsePoint Newsletter.
Topics: Coronary IVL, Peripheral IVL, IVL Technology, Coronary Clinical Data, Peripheral Conferences, Peripheral Clinical Data, SWAV News, Shockwave C2, Coronary Conferences, Shockwave S4, PulsePoint Newsletter, Calcium Corner, Shockwave M5 & Shockwave M5+, Reimbursement, Treating Different Ca++ Morphologies, Female vs. Male Outcomes, Empower CAD, Reducer
But, right now we're in the early phases of the R&D program. In the meantime, don't miss the IVL application that heart teams are embracing already — maintaining transfemoral TAVR access through heavily calcified iliacs by using IVL.
